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INTRODUCTION
Obesity is an abnormal condition characterized by excessive ac-
cumulation of body fat. In general, high body mass index (BMI) is 
indicative of obesity. The prevalence of obesity and excess weight 
has increased, accounting for more than a third of the world’s 
population in recent years.1 Obesity underlies conditions such as 
cardiovascular disease, hypertension, diabetes mellitus, nonalco-
holic fatty liver disease (NAFLD), gallbladder disease, pancreatitis, 
sleep apnea, and osteoarthritis.2 These diseases lead to chronic 
disability in obese people. Obesity is also an independent factor 
for the development of various cancers3 and is closely associated 
with cancer regardless of age, sex, race, and type of cancer.4 Can-
cer-related mortality is high in obese patients with prostate can-
cer, breast cancer, and colorectal cancer.5
Primary liver cancer is one of the most common malignancies 
and the associated mortality rate corresponds to 9% of all cancer-
related deaths worldwide.6 Hepatocellular carcinoma (HCC) is the 
most common type of primary liver cancer and accounts for ap-
proximately 80–90% of all cases of primary liver cancer. The 
common causes of HCC are viral hepatitis (hepatitis B or C virus), 
alcohol, smoking, and diabetes mellitus.7
Studies have been conducted to investigate whether obesity is a 
risk factor for the occurrence of primary liver cancer. Some studies 
have found that obesity is a risk factor for HCC occurrence, while 
Chen et al. reported a lack of association between obesity and 
HCC occurrence.8-10 However, studies suggesting the relationship 
between obesity and primary liver cancer may suffer from risk of 
bias because they were conducted as case-control or retrospec-
tive cohort studies. Hence, the present study was conducted to 
analyze prospective cohorts to determine the relationship be-
tween BMI and primary liver cancer. We aimed to clarify the effect 
of obesity on the occurrence of and mortality from primary liver 
cancer using systematic review and meta-analysis.
Background/Aims: In this systematic review and meta-analysis, we aimed to clarify the effect of obesity on the 
occurrence of and mortality from primary liver cancer. 
Methods: This study was conducted using a systematic literature search of MEDLINE, EMBASE, and the Cochrane Library 
until November 2018 using the primary keywords “obesity,” “overweight,” “body mass index (BMI),” “body weight,” “liver,” 
“cancer,” “hepatocellular carcinoma,” “liver cancer,” “risk,” and “mortality.” Studies assessing the relationship between 
BMI and occurrence of or mortality from primary liver cancer in prospective cohorts and those reporting hazard ratios 
(HRs) or data that allow HR estimation were included.
Results: A total of 28 prospective cohort studies with 8,135,906 subjects were included in the final analysis. These 
included 22 studies with 6,059,561 subjects for cancer occurrence and seven studies with 2,077,425 subjects for cancer-
related mortality. In the meta-analysis, an increase in BMI was associated with the occurrence of primary liver cancer (HR, 
1.69; 95% confidence interval, 1.50–1.90, I2=56%). A BMI-dependent increase in the risk of occurrence of primary liver 
cancer was reported. HRs were 1.36 (95% CI, 1.02–1.81), 1.77 (95% CI, 1.56–2.01), and 3.08 (95% CI, 1.21–7.86) for BMI >25 
kg/m2, >30 kg/m2, and >35 kg/m2, respectively. Furthermore, increased BMI resulted in enhanced liver cancer-related 
mortality (HR, 1.61; 95% CI, 1.14–2.27, I2=80%).
Conclusions: High BMI increases liver cancer mortality and occurrence of primary liver cancer. Obesity is an independent 
risk factor for the occurrence of and mortality from primary liver cancer. (Clin Mol Hepatol 2021;27:157-174)
Keywords: Obesity; Liver cancer; Carcinoma, Hepatocellular; Risk; Mortality
Study Highlights
1. An increase in BMI was associated with the occurrence of primary liver cancer (HR, 1.69).
2. A BMI-dependent occurrence of primary liver cancer was reported. HRs were 1.36, 1.77, and 3.08 for BMI >25 kg/m2, >30 kg/m2, and >35 kg/m2, re-
spectively.
3. Increased BMI resulted in enhanced liver cancer-related mortality (HR, 1.61).
4. Obesity is an independent risk factor for the occurrence of and mortality from primary liver cancer.
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We searched for all relevant studies published from January 
1990 to November 2018 that investigated the relationship be-
tween obesity and risk of primary liver cancer. We used MEDLINE, 
EMBASE, and Cochrane Library databases. The fundamental con-
cept of the data search for the systematic review and meta-analy-
sis was as follows: (obesity) OR (obese) OR (overweight) OR (body 
weight) OR (body mass index) AND (hepatocellular carcinoma) OR 
([liver] AND [cancer] AND [‘risk’ OR ‘mortality’]). However, there 
were slight differences in the detailed searching methods among 
the three databases, as each database has its own search formu-
la. The detailed search methods used for each database are de-
scribed in the Supplementary Material 1. Further, reference lists of 
the searched articles were checked to identify additional studies. 
All human studies written in English were examined, and the lat-
est date for searching the relevant studies was November 8, 2018.
Study selection
First, we checked the titles and abstracts of the selected papers 
to exclude irrelevant articles. Second, the complete text of all se-
lected researches was reviewed based on the inclusion and exclu-
sion criteria. The inclusion criteria were: 1) patients: the subjects 
who participated in the studies on primary liver cancer; 2) inter-
vention: obesity; 3) comparator: non-obese subjects; 4) outcome: 
occurrence or cancer-related mortality of primary liver cancer in-
cluding HCC; and 5) study design: prospective cohort study. We 
excluded irrelevant studies according to the following criteria: 
1) publications in a language other than English; 2) abstract-only 
publications or unpublished studies; 3) non-original articles; and 
4) animal studies. In case of overlapping cohorts, we included 
only one study that had the largest number of subjects and ex-
cluded the other studies. In this meta-analysis, we included stud-
ies that presented hazard ratios (HRs) estimated using Cox pro-
portional hazards model, because this model is suitable for 
analyzing cancer occurrence and cancer-related mortality. Previ-
ous meta-analyses for the relationship between obesity and pri-
mary liver cancer were reported before 2012.11-13 The present 
study included original studies published after 2012 in addition to 
the studies included in the previous meta-analyses. However, 
among the studies included in the previous meta-analyses, we ex-
cluded several retrospective studies, overlapping cohort studies, 
and studies that were not analyzed using Cox proportional hazard 
model. The eligibility of the studies was independently assessed 
by two reviewers (W. Sohn and S. Lee). In case of disagreement, 
we re-reviewed the studies and determined whether they were 
relevant for the final analysis based on discussion and consensus. 
A third investigator (H.W. Lee) determined the eligibility if the 
suitability of a study could not be determined even after re-evalu-
ation.
A formal quality assessment of studies was performed to under-
stand the risk of bias in each study. The methodological quality of 
the studies was independently evaluated by two investigators (W. 
Sohn and S. Lee) using the Newcastle-Ottawa scale for observa-
tional study.14 The scoring scale comprised three categories, 
namely, selection (four questions), comparability of study groups 
(two questions), and ascertainment of exposure or outcome (three 
questions). A cumulative score of more than 7 was reflective of 
the high quality of the study.15-17 
Data extraction
Two reviewers (W. Sohn and S. Lee) independently extracted 
the necessary information and filled up the data form for analysis. 
The variables for the analysis were author, region, publication 
year, study period, definition of overweight or obesity according 
to BMI, number of subjects, hepatitis B virus status, hepatitis C 
virus status, use of alcohol, diabetes mellitus, and the parameters 
adjusted in each study.
The primary endpoint was the occurrence of primary liver can-
cer, including HCC. We assessed the primary endpoint as HR with 
95% confidence interval (CI) by comparing the subjects with/
without obesity or being overweight. The secondary end point 
was liver cancer-related mortality and was evaluated by HR with 
95% CI.
Statistical analysis
Meta-analyses were performed to calculate pooled HRs with 
95% CIs.18 A random effect model was used in the meta-analysis. 
Subgroup analysis was performed according to cut-off values of 
BMI because the definitions of obesity were different from each 
other. Obesity group was defined based on cut-off values of BMI: 
>35 kg/m2, >30 kg/m2, and >25 kg/m2. We categorized obesity 
group of the studies with cut-off values of BMI >27.5 kg/m2 and 
>27 kg/m2 as obesity group with a cut-off value of BMI >25 kg/m2, 
because there was only a small number of studies with these cut-
160 http://www.e-cmh.orghttps://doi.org/10.3350/cmh.2020.0176
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off values of. We also performed subgroup analyses according to 
ethnic group (Asian vs. non-Asian) and viral hepatitis (hepatitis B 
virus or hepatitis C virus). Statistical heterogeneity was assessed 
using I 2 statistics, with values >50% suggestive of significant het-
erogeneity.19 Publication bias was examined using the Egger’s re-
gression test20 and was also qualitatively assessed by inspecting 
funnel plots of the logarithmic HR versus their standard errors.21 
The test for funnel plot asymmetry was not conducted if the in-
cluded studies were fewer than 10.22 To assess the effect of mean 
age and male proportion of study participants on the effect size, 
meta-regression analysis based on a random-effects model was 
performed. All P-values were two-tailed, and a value of P<0.05 
was considered statistically significant in all tests (except for the 
heterogeneity and Egger’s regression tests). Analysis and report-
ing were performed according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses guidelines.23 All statis-
tical procedures were conducted using the statistical software Re-
view Manager 5.3 (version 5.3.5; Cochrane Collaboration, Copen-
hagen, Denmark), with the exception of the meta-regression and 
publication bias analyses, which were performed using R (version 
4.0.2; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Study selection
A flow diagram of our literature search is shown in Figure 1. In 
summary, 4,108 studies were evaluated in our literature search 
and 1,055 duplicate articles were excluded from the three search 
engines. In addition, 2,840 other irrelevant articles were excluded 
based on the titles and abstracts. Two reviewers independently 
evaluated the complete text of the 213 remaining articles for their 
eligibility. Thereafter, 185 articles were excluded for the following 
reasons: study did not report relevant outcomes (n=140), non-
prospective studies (n=17), abstract only (n=11), non-original arti-
cles (n=9), cohort overlap between studies (n=7), and non-cohort 
studies (n=1). Finally, 28 studies with 8,135,906 subjects were se-
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lected for the systematic review and meta-analysis.24-51 
Study characteristics
The characteristics of the included studies for meta-analysis are 
described in Table 1. These studies were published between 2003 
and 2018, and the enrollment period ranged from 1972 to 2013. 
The regions where the studies were conducted included the USA 
(n=5), Europe (n=10), and Asia (n=13). According to the Newcas-
tle-Ottawa scale, 79% (22/28) of the studies were deemed to be 
of high quality (score ≥7).
Table 2 shows the clinical characteristics of the subjects in the 
included studies. Seven studies reported clinical outcomes (prima-
ry or secondary endpoint) separately only based on sex. There-
fore, we considered these studies as different reports and per-
formed the meta-analysis based on the population of men and 
women. The obesity group was defined based on a BMI of >35 
kg/m2 in four studies, >30 kg/m2 in 23 studies, >27.5 kg/m2 in 
two studies, >27 kg/m2 in one study, and >25 kg/m2 in five stud-
ies. While HRs for liver cancer occurrence were reported in 26 
studies, those for cancer-related mortality were reported in 10 
studies. One study showed HRs for both the occurrence of and 
Table 1. Characteristics of the studies included in the meta-analysis
Study Region Study period Number of subjects Male (%)
Newcastle-Ottawa scale
Selection Comparability Outcome
Calle et al.24 (2003) USA 1982–1988 900,053 45.0 **** * ***
Batty et al.25 (2005) UK 1967–2002 18,403 100.0 *** * **
Kuriyama et al.26 (2005) Japan 1984–1992 27,539 45.3 *** * **
Rapp et al.27 (2005) Austria 1985–2002 145,931 46.2 *** * **
N’Kontchou et al.28 (2006) France 1994–2004 771 64.3 **** ** *
Jee et al.29 (2008) Korea 1992–2006 1,213,829 63.5 *** * *
Joshi et al.30 (2008) Korea 1998–2004 548,530 100.0 *** ** **
Inoue et al.31 (2009) Japan 1993–2006 17,590 34.6 **** ** **
Wang et al.32 (2009) Taiwan 1997–2004 5,929 43.5 *** ** **
Hart et al.33 (2010) Scotland 1965–2007 26,738 61.8 **** * ***
Chao et al.34 (2011) Taiwan 1989–2006 1,142 100.0 **** ** ***
Hung et al.35 (2011) Taiwan 1999–2009 1,470 52.1 **** ** ***
Borena et al.36 (2012) Europe 1972–2006 578,700 50.1 **** * ***
Chen et al.37 (2013) Taiwan 2004–2007 56,231 30.9 **** ** **
Li et al.38 (2013) Japan 1988–2009 72,473 42.8 **** * ***
Loomba et al.39 (2013) Taiwan 1991–2004 23,712 50.3 **** ** ***
Song et al.40 (2014) Europe 1972–2008 54,725 48.7 **** * ***
Meyer et al.41 (2015) Europe 1977–2008 35,784 47.2 **** * **
Campbell et al.42 (2016) USA 1980–2011 1,570,023 40.8 *** * **
Liu et al.43 (2016) China 1996–2013 68,253 0.0 **** * **
Setiawan et al.44 (2016) USA 1993–2010 168,476 46.3 **** * ***
McMahon et al.45 (2017) USA 1995–2012 1,080 49.3 **** ** **
Nderitu et al.46 (2017) Sweden 1985–2011 65,224 57.2 **** * **
Yang et al.47 (2017) USA 1995–2011 297,928 58.5 *** * **
Brichler et al.48 (2019) France 2006–2012 317 82.3 **** ** **
Hagström et al.49 (2018) Sweden 1969–2012 1,220,261 100.0 **** * **
Jeong et al.50 (2018) Korea 2002–2013 510,148 54.3 **** * ***
Yi et al.51 (2018) Korea 2002–2013 504,646 54.3 **** ** **
162 http://www.e-cmh.orghttps://doi.org/10.3350/cmh.2020.0176
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mortality from primary liver cancer.45 The adjustable variables for 
primary or secondary endpoint were factors such as age, sex, al-
cohol, and smoking.
Occurrence of and cancer-related mortality from 
primary liver cancer
Figure 2 indicates the meta-analysis of the occurrence of and 
mortality from primary liver cancer in the included studies. The 
pooled HR for the occurrence of primary liver cancer was 1.69 
(95% CI, 1.50–1.9, I 2=56%) (Fig. 2A). A BMI-dependent increase 
in the risk of occurrence of primary liver cancer was reported. The 
values of HRs were 1.36 (95% CI, 1.02–1.81), 1.77 (95% CI, 
1.56–2.01), and 3.08 (95% CI, 1.21–7.86) for BMI >25 kg/m2, 
>30 kg/m2, and >35 kg/m2, respectively. The value of pooled HR 
was 1.61 (95% CI, 1.14–2.27, I 2=80%) for cancer-related mortali-
Figure 2. Forest plots of all the studies analyzing the occurrence (A) and cancer-related mortality (B) from primary liver cancer. SE, standard error; CI, 
confidence interval; BMI, body mass index. 
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
1.1.1 BMI ≥35 kg/m2
Song et al.40 (2014), men 1.459 0.61 0.9 4.30 (1.30, 14.22)
Song et al.40 (2014), women 0.593 0.77 0.6 1.81 (0.40, 8.18)
Subtotal (95% CI) 1.5 3.08 (1.21, 7.86)
Heterogeneity: Tau2=0.00; chi2=0.78, df=1 (P=0.38); I2=0%
Test for overall effect: Z=2.35 (P=0.02)
1.1.2 BMI ≥30 kg/m2
Rapp et al.27 (2005) 0.513 0.408 1.8 1.67 (0.75, 3.72)
N’Kontchou et al.28 (2006) 1.03 0.172 5.3 2.80 (2.00, 3.92)
Jee et al.29 (2008), men 0.489 0.127 6.5 1.63 (1.27, 2.09)
Jee et al.29 (2008), women 0.329 1.68 5.4 1.39 (1.00, 1.93)
Wang et al.32 (2009) 0.531 0.261 3.5 1.70 (1.02, 2.84)
Borena et al.36 (2012) 0.728 0.161 5.6 2.07 (1.51, 2.84)
Loomba et al.39 (2013) 0.385 0.223 4.1 1.47 (0.95, 2.28)
Meyer et al.41 (2015) 0.793 0.32 2.6 2.21 (1.18, 4.14)
Campbell et al.42 (2016) 0.56 0.059 8.3 1.75 (1.56, 1.97)
Liu et al.43 (2016) 0.673 0.276 3.2 1.96 (1.14, 3.37)
Setiawan et al.44 (2016), men 0.599 0.168 5.4 1.82 (1.31, 2.53)
Setiawan et al.44 (2016), women 0.278 0.237 3.9 1.32 (0.83, 2.10)
Hagström et al.49 (2018) 1.278 0.338 2.4 3.59 (1.85, 6.96)
McMahon et al.45 (2017) 0.058 0.383 2.0 1.06 (0.50, 2.24)
Nderitu et al.46 (2017) 0.718 0.366 2.2 2.05 (1.00, 4.20)
Yang et al.47 (2017) 0.784 0.154 5.8 2.19 (1.62, 2.96)
Brichler et al.48 (2019) 0.982 0.481 1.4 2.67 (1.04, 6.85)
Yi et al.51 (2018) 0.157 0.117 6.8 1.17 (0.93, 1.47)
Subtotal (95% CI) 76.2 1.77 (1.56, 2.01)
Heterogeneity: Tau2=0.03; chi2=34.63, df=17 (P=0.007); I2=51%
Test for overall effect: Z=8.82 (P<0.00001)
1.1.3 BMI ≥25 kg/m2
Kuriyama et al.26 (2005), men 0.131 0.463 1.5 1.14 (0.46, 2.82)
Kuriyama et al.26 (2005), women -0.094 0.566 1.1 0.91 (0.30, 2.76)
Inoue et al.31 (2009) 0.798 0.228 4.0 2.22 (1.42, 3.47)
Chao et al.34 (2011) 0.457 0.158 5.7 1.58 (1.16, 2.15)
Hung et al.35 (2011) 0.27 0.23 4.0 1.31 (0.83, 2.06)
Chen et al.37 (2013) -0.02 0.143 6.1 0.98 (0.74, 1.30)
Subtotal (95% CI) 22.3 1.36 (1.02, 1.81)
Heterogeneity: Tau2=0.06; chi2=11.36, df=5 (P=0.04); I2=56%
Test for overall effect: Z=2.10 (P=0.04)
Total (95% CI) 100.0 1.69 (1.50, 1.91)
Heterogeneity: Tau2=0.04; chi2=56.45, df=25 (P=0.0003); I2=56%
Test for overall effect: Z=8.45 (P<0.00001)    0.05                0.2                             1                             5                     20
Test for suborouo differences: chi2=4.22, df=2 (P=0.12); I2=52.6% Favours (obese)           Favours (non-obese)
A
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ty of primary liver cancer (Fig. 2B). A relationship seemed to exist 
between BMI and mortality from primary liver cancer. The values 
of HRs were 1.25 (95% CI, 0.97–1.61), 1.37 (95% CI, 0.93–2.02), 
and 2.82 (95% CI, 1.07–7.43) for BMI >25 kg/m2, >30 kg/m2, and 
>35kg/m2, respectively.
Primary and secondary endpoints were evaluated for Asian sub-
jects and non-Asian subjects (Fig. 3). The pooled HR for the oc-
currence of primary liver cancer was 1.42 (95% CI, 1.23–1.63, 
I 2=37%) (Fig. 3A) among Asian subjects. A BMI-dependent in-
crease in the risk of occurrence of primary liver cancer was ob-
served in Asian subjects; the HR values were 1.36 (95% CI, 1.02–
1.82) and 1.44 (95% CI, 1.24–1.67) for BMI >25 and >30 kg/m2, 
respectively. Among Asian subjects, the pooled HR was 1.24 
(95% CI, 1.05–1.46, I 2=0%) for mortality from primary liver can-
cer (Fig. 3B); the HR values were 1.25 (95% CI, 0.97–1.61) and 
1.23 (95% CI, 0.98–1.53) for BMI >25 and >30 kg/m2, respec-
tively. The pooled HR for the occurrence of primary liver cancer 
was 2.00 (95% CI, 1.73–2.31, I 2=32%) among non-Asian sub-
jects (Fig. 3C). A BMI-dependent increase in the risk of occurrence 
of primary liver cancer was also observed in non-Asian subjects; 
the HR values were 1.98 (95% CI, 1.71–2.29) and 3.08 (95% CI, 
1.21–7.86) for BMI >30 and >35 kg/m2, respectively. Among non-
Asian subjects, the pooled HR was 2.10 (95% CI, 1.03–4.26, 
I 2=85%) for mortality from primary liver cancer (Fig. 3D); the HR 
values were 1.75 (95% CI, 0.71–4.31) and 2.82 (95% CI, 1.07–
7.43) for BMI >30 and >35 kg/m2, respectively. We also assessed 
cancer occurrence in five studies on patients with viral hepatitis 
(hepatitis B virus or hepatitis C virus), which is a high-risk popula-
tion for primary liver cancer (Supplementary Fig. 1). The HR for 
cancer occurrence in patients with viral hepatitis was 1.76 (95% 
CI, 1.22–2.54, I 2=66%), and this value was higher than that re-
ported for the whole population. A BMI-dependent increase in 
the risk of occurrence of primary liver cancer among patients with 
viral hepatitis was observed (Supplementary Fig. 1A); the HR val-
ues were 1.49 (95% CI, 1.15–1.92) and 2.07 (95% CI, 1.11–3.85) 
for BMI >25 and >30 kg/m2, respectively.
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
1.2.1 BMI ≥35 kg/m2
Calle et al.24 (2003), men 1.509 0.219 11.7 4.52 (2.94, 6.95)
Calle et al.24 (2003), women 0.519 0.302 10.0 1.68 (0.93, 3.04)
Subtotal (95% CI) 21.7 2.82 (1.07, 7.43)
Heterogeneity: Tau2=0.42; chi2=7.04, df=1 (P=0.008); I2=86%
Test for overall effect: Z=2.09 (P=0.04)
1.2.2 BMI ≥30 kg/m2
Batty et al.25 (2005) 1.324 0.519 6.4 3.76 (1.36, 10.39)
Joshi et al.30 (2008) 0.077 0.244 11.2 1.08 (0.67, 1.74)
Hart et al.33 (2010), men 1.115 0.423 7.8 3.05 (1.33, 6.99)
Hart et al.33 (2010), women 0.104 0.781 3.7 1.11 (0.24, 5.13)
McMahon et al.45 (2017) -0.236 0.233 11.4 0.79 (0.50, 1.25)
Jeong et al.50 (2018) 0.239 0.127 13.2 1.27 (0.99, 1.63)
Subtotal (95% CI) 53.7 1.37 (0.93, 2.02)
Heterogeneity: Tau2=0.12; chi2=13.22, df=5 (P=0.02); I2=62%
Test for overall effect: Z=1.59 (P=0.11)
1.2.3 BMI ≥25 kg/m2
Li et al.38 (2013), men 0.14 0.166 12.6 1.15 (0.83, 1.59)
Li et al.38 (2013), women 0.351 0.205 11.9 1.42 (0.95, 2.12)
Subtotal (95% CI) 24.6 1.25 (0.97, 1.61)
Heterogeneity: Tau2=0.00; chi2=0.64, df=1 (P=0.42); I2=0%
Test for overall effect: Z=1.73 (P=0.08)
Total (95% CI) 100.0 1.61 (1.14, 2.27)
Heterogeneity: Tau2=0.22; chi2=45.09, df=9 (P<0.00001); I2=80%
Test for overall effect: Z=2.70 (P=0.007)  0.1          0.2                   0.5              1                2                      5             10
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Figure 3. Subgroup analysis according to ethnic group (Asian vs. non-Asian): the occurrence of (A, C) and cancer-related mortality (B, D) from primary 
liver cancer in Asian subjects (A, B) and non-Asian subjects (C, D). SE, standard error; CI, confidence interval; BMI, body mass index.
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
2.1.1 BMI ≥30 kg/m2
Jee et al.29 (2008), men 0.489 0.127 14.0 1.63 (1.27, 2.09)
Jee et al.29 (2008), women 0.329 0.168 10.6 1.39 (1.00, 1.93)
Wang et al.32 (2009) 0.531 0.261 5.9 1.70 (1.02, 2.84)
Loomba et al.39 (2013) 0.385 0.223 7.4 1.47 (0.95, 2.28)
Liu et al.43 (2016) 0.658 0.269 5.5 1.93 (1.14, 3.27)
Yi et al.51 (2018) 0.157 0.117 15.0 1.17 (0.93, 1.47)
Subtotal (95% CI) 58.3 1.44 (1.24, 1.67)
Heterogeneity: Tau2=0.00; chi2=5.74, df=5 (P=0.33); I2=13%
Test for overall effect: Z=4.89 (P<0.00001)
2.1.2 BMI ≥25 kg/m2
Kuriyama et al.26 (2005), men 0.131 0.463 2.2 1.14 (0.46, 2.82)
Kuriyama et al.26 (2005), women -0.094 0.566 1.5 0.91 (0.30, 2.76)
Inoue et al.31 (2009) 0.798 0.228 7.1 2.22 (1.42, 3.47)
Chao et al.34 (2011) 0.457 0.158 11.3 1.58 (1.16, 2.15)
Hung et al.35 (2011) 0.27 0.233 6.9 1.31 (0.83, 2.07)
Chen et al.37 (2013) -0.02 0.143 12.5 0.98 (0.74, 1.30)
Subtotal (95% CI) 41.7 1.36 (1.02, 1.82)
Heterogeneity: Tau2=0.06; chi2=11.36, df=5 (P=0.04); I2=56%
Test for overall effect: Z=2.10 (P=0.04)
Total (95% CI) 100.0 1.42 (1.23, 1.63)
Heterogeneity: Tau2=0.02; chi2=17.56, df=11 (P=0.09); I2=37%
Test for overall effect: Z=4.83 (P<0.00001)     0.1         0.2                  0.5              1                2                     5             10
Test for suborouo differences: chi2=0.12, df=1 (P=0.73); I2=0%                             Favours (obese)            Favours (non-obese)
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
2.2.1 BMI ≥30 kg/m2
Joshi et al.30 (2008) 0.077 0.244 12.1 1.08 (0.67, 1.74)
Jeong et al.50 (2018) 0.239 0.127 44.6 1.27 (0.99, 1.63)
Subtotal (95% CI) 56.7 1.23 (0.98, 1.53)
Heterogeneity: Tau2=0.00; chi2=0.35, df=1 (P=0.56); I2=0%
Test for overall effect: Z=1.82 (P=0.07)
2.2.2 BMI ≥25 kg/m2
Li et al.38 (2013), men 0.14 0.166 26.1 1.15 (0.83, 1.59)
Li et al.38 (2013), women 0.351 0.205 17.1 1.42 (0.95, 2.12)
Subtotal (95% CI) 43.3 1.25 (0.97, 1.61)
Heterogeneity: Tau2=0.00; chi2=0.64, df=1 (P=0.42); I2=0%
Test for overall effect: Z=1.73 (P=0.08)
Total (95% CI) 100.0 1.24 (1.05, 1.46)
Heterogeneity: Tau2=0.00; chi2=1.00, df=3 (P=0.80); I2=0%
Test for overall effect: Z=2.51 (P=0.01)     0.1         0.2                  0.5              1                2                     5             10
Test for suborouo differences: chi2=0.01, df=1 (P=0.91); I2=0%                             Favours (obese)            Favours (non-obese)
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Figure 3. Continued.
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
2.3.1 BMI ≥35 kg/m2
Song et al.40 (2014), men 1.459 0.61 1.4 4.30 (1.30, 14.22)
Song et al.40 (2014), women 0.593 0.77 0.9 1.81 (0.40, 8.18)
Subtotal (95% CI) 2.2 3.08 (1.21, 7.86)
Heterogeneity: Tau2=0.00; chi2=0.78, df=1 (P=0.38); I2=0%
Test for overall effect: Z=2.35 (P=0.02)
2.3.2 BMI ≥30 kg/m2
Rapp et al.27 (2005) 0.513 0.406 2.9 1.67 (0.75, 3.72)
N’Kontchou et al.28 (2006) 1.03 0.172 11.0 2.80 (2.00, 3.92)
Borena et al.36 (2012) 0.728 0.161 11.9 2.07 (1.51, 2.84)
Meyer et al.41 (2015) 0.793 0.32 4.4 2.21 (1.18, 4.14)
Campbell et al.42 (2016) 0.56 0.059 23.9 1.75 (1.56, 1.97)
Setiawan et al.44 (2016), men 0.599 0.168 11.3 1.82 (1.31, 2.53)
Setiawan et al.44 (2016), wemen 0.278 0.237 7.1 1.32 (0.83, 2.10)
Hagström et al.49 (2018) 1.278 0.338 4.0 3.59 (1.85, 6.96)
McMahon et al.45 (2017) 0.058 0.383 3.2 1.06 (0.50, 2.24)
Nderitu et al.46 (2017) 0.718 0.366 3.5 2.05 (1.00, 4.20)
Yang et al.47 (2017) 0.784 0.154 12.5 2.19 (1.62, 2.96)
Brichler et al.48 (2019) 0.982 0.481 2.1 2.67 (1.04, 6.86)
Subtotal (95% CI) 97.8 1.98 (1.71, 2.29)
Heterogeneity: Tau2=0.02; chi2=17.26, df=11 (P=0.10); I2=36%
Test for overall effect: Z=9.18 (P<0.00001)
Total (95% CI) 100.0 2.00 (1.73, 2.31)
Heterogeneity: Tau2=0.02; chi2=19.09, df=13 (P=0.12); I2=32%
Test for overall effect: Z=9.50 (P<0.00001)   0.1         0.2                  0.5              1                2                     5             10
Test for suborouo differences: chi2=0.83, df=1 (P=0.36); I2=0%                             Favours (obese)            Favours (non-obese)
Study of subgroup Log (hazard ratio) SE Weight (%)
Hazard ratio
IV, random, 95% CI
Hazard ratio
IV, random, 95% CI
2.4.1 BMI ≥35 kg/m2
Calle et al.24 (2003), men 1.509 0.219 19.8 4.52 (2.94, 6.95)
Calle et al.24 (2003), women 0.519 0.302 18.6 1.68 (0.93, 3.04)
Subtotal (95% CI) 38.4 2.82 (1.07, 7.43)
Heterogeneity: Tau2=0.42; chi2=7.04, df=1 (P=0.0006); I2=86%
Test for overall effect: Z=2.09 (P=0.04)
2.4.2 BMI ≥30 kg/m2
Batty et al.25 (2005) 1.324 0.519 14.8 3.76 (1.36, 10.39)
Hart et al.33 (2010), men 1.115 0.423 16.5 3.05 (1.33, 6.99)
Hart et al.33 (2010), women 0.104 0.781 10.7 1.11 (0.24, 5.13)
McMahon et al.45 (2017) -0.236 0.233 19.6 0.79 (0.50, 1.25)
Subtotal (95% CI) 61.6 1.75 (0.71, 4.31)
Heterogeneity: Tau2=0.61; chi2=12.84, df=3 (P=0.005); I2=77%
Test for overall effect: Z=1.22 (P=0.22)
Total (95% CI) 100.0 2.10 (1.03, 4.26)
Heterogeneity: Tau2=0.61; chi2=33.11, df=5 (P<0.00001); I2=85%
Test for overall effect: Z=2.05 (P=0.04)  0.1          0.2                   0.5              1                2                      5             10
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Publication bias
Egger’s regression test showed no significant publication bias in 
cancer occurrence and cancer-related mortality in the whole pop-
ulation (P=0.652 and P=0.490, respectively). Furthermore, no 
asymmetry was observed on visual inspection of the funnel plots 
(Supplementary Fig. 2).
Meta-regression analysis
Supplementary Figure 3 shows the results of meta-regression 
analysis for predicting HR for incidence or mortality according to 
mean age of the included studies. The mean age in each study 
was not associated with the risk of primary liver cancer occur-
rence or mortality (increased HR per 1 year-old of age: incidence, 
0.998 [95% CI, 0.976–1.021]; mortality, 1.021 [0.965–1.079]). 
There was no significant difference in the relationship between 
obesity and the occurrence of and mortality from primary liver 
cancer according to age. As shown in Supplementary Figure 4, 
the proportion of males was also not associated with the risk of 
primary liver cancer occurrence or mortality (increased HR per one 
percentage of male proportion: incidence, 1.003 [95% CI, 0.998–
1.009]; mortality, 1.004 [0.996–1.013]). There was no significant 
difference in the relationship between obesity and the occurrence 
of and mortality from primary liver cancer according to sex.
DISCUSSION
The present systematic review and meta-analysis were conduct-
ed to clarify whether obesity is an independent risk factor for the 
occurrence of and mortality from primary liver cancer. A total of 
28 prospective cohort studies were finally included for the analy-
sis. Obesity is defined based on BMI, and the findings of this 
study indicate that a high BMI value increases the risk of occur-
rence of and mortality from primary liver cancer. Furthermore, a 
BMI-dependent increase was observed for the risk of the occur-
rence of and mortality from primary liver cancer.
According to the World Health Organization report, an estimat-
ed 2.8 million people die each year worldwide owing to excess 
weight or obesity and 35.8 million global disability-adjusted life 
years result from by excess weight and obesity.52 The risk for de-
veloping cardiovascular diseases such as coronary heart disease 
and cerebrovascular disease and metabolic diseases such as type 
2 diabetes mellitus consistently increase with an increase in BMI. 
The increased BMI raises the risk of cancers of the breast, colon, 
prostate, endometrium, kidney, and gall bladder.52
Mechanisms of hepatocarcinogenesis in obesity are thought to 
be as follows: First, the liver is a major organ for fat storage. Pro-
inflammatory cytokines (i.e., tumor necrosis factor-alpha and in-
terleukin-6) secreted by the adipose tissue are oncogenic signal-
ing mediators of liver cancer.53 The pro-inflammatory action of 
adipokines (i.e., leptin) and lipotoxicity induce carcinogenesis 
through proliferation or oncogenic mutations as well as inflamma-
tory response.54 Second, insulin resistance or hyperinsulinemia is 
an important feature of cell proliferation accompanied with obesi-
ty.55 Finally, obesity induces changes in the gut microbiome that 
contribute to carcinogenesis. For instance, deoxycholic acid in-
duced by intestinal microbiome leads to DNA damage and influ-
ences cancer development in obese mice.56
However, the role of obesity as a risk factor of primary liver can-
cer is not clearly understood through clinical data, although 
NAFLD, a disease that develops in response to increased BMI, is a 
cause of primary liver cancer. The most common etiology of pri-
mary liver cancer is chronic hepatitis B or C infection and chronic 
alcohol consumption, while NAFLD-related primary liver cancer 
only affects a small percentage of patients.57 In recent years, obe-
sity has gained attention as a risk factor of primary liver cancer, 
owing to an increase in its prevalence. Many studies including few 
meta-analyses have evaluated the effect of obesity on the risk of 
primary liver cancer. However, the findings of these studies may 
involve a risk of bias because most of them were conducted using 
retrospective cohorts as case-control studies. There exist some 
differences in the evaluation of the risk of cancer in each study, 
including relative risk (RR), odds ratio (OR), and HR. Moreover, the 
OR-related RR was considered the same as HR-related RR in some 
meta-analyses. Hence, this systematic review and meta-analysis 
included only prospective cohort studies that reported HR, which 
is useful when the risk is not constant with respect to time.
The main finding of this study is that high BMI increases the oc-
currence of primary liver cancer. In particular, a BMI-dependent 
increase in the risk of occurrence of primary liver cancer was re-
ported with pooled HRs of 1.36, 1.77, and 3.08 for BMI >25, 
>30, and >35 kg/m2, respectively. This finding is consistent with 
that reported in previous meta-analyses.11-13 The previous meta-
analyses were conducted based on the original studies before 
2012. The present meta-analysis included original studies after 
2012 in addition to the studies included in the previous meta-
analyses. Therefore, we performed a meta-analysis for cancer oc-
currence and cancer-related mortality according to the publication 
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year of the included studies (before 2012/after 2012). The results 
are shown in Supplementary Figure 5. The pooled HR for the oc-
currence of primary liver cancer in subjects with BMI >30 kg/m2 in 
the studies before and after the publication year 2012 was 1.85 
(95% CI, 1.49–2.30, I 2=52%) and 1.73 (95% CI, 1.47–2.04, 
I 2=53%), respectively. These results were consistent with those of 
the included studies regardless of the publication year. The sec-
ondary endpoint of this study was the mortality related to primary 
liver cancer. An increase in BMI was found to correlate with a rise 
in liver cancer-related mortality. Thus, obesity increases liver can-
cer-related mortality as well as the risk of occurrence of primary 
liver cancer.
The criteria of obesity in Asian people are different from those 
in Western people.58 We evaluated the differences in the effect of 
obesity on primary liver cancer in Asian and non-Asian subjects. 
Among Asian subjects, an increase in BMI resulted in a rise in the 
occurrence of and mortality related to primary liver cancer. More-
over, this study showed that high BMI increases cancer occurrence 
and cancer-related mortality in subjects with hepatitis B or C, 
which are high-risk groups for primary liver cancer. Considering 
these findings, obesity may serve as an independent factor for the 
occurrence and cancer-related mortality regardless of region and 
viral hepatitis.
This study has several limitations. First, it included studies that 
reported BMI as a categorical variable. We could not include 
those studies that reported the relationship between clinical out-
comes and BMI as a continuous variable because it is not possible 
to integrate both categorical and continuous variables. Second, 
obesity was defined based on BMI. Obesity may be assessed 
more accurately if body fat measurement was carried out using 
other methods such as bioelectrical impedance analysis. Finally, 
this study showed that the risk of the occurrence of and mortality 
from primary liver cancer increased as BMI increased (>25 kg/m2). 
However, low BMI was associated with poor prognosis in patients 
with liver disease other than liver cancer. Yi et al.59 reported that 
the mortality from alcoholic liver disease was significantly high in 
male subjects with lower BMI (<21 kg/m2). Further studies are 
needed to clarify the diverse effect of BMI on the prognosis in pa-
tients with liver disease considering etiology, sex, and alcohol 
consumption. In spite of these limitations, the findings established 
herein provide evidence for the effect of obesity on primary liver 
cancer based on prospective cohort studies.
In conclusion, high BMI increases liver cancer mortality and oc-
currence of primary liver cancer. Obesity is an independent risk 
factor for the occurrence of and mortality associated with primary 
liver cancer.
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